← Patent-cliff monitor small molecule ITOVEBI INAVOLISIB
Loss of exclusivity June 2038 latest FDA-listed patent expiry
Company Genentech → See this company's full patent-cliff portfolio Drug detail Brand name ITOVEBI Active ingredient INAVOLISIB Strength 3MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval October 2024 Marketing status RX
Listed patents Patent Expires Type 12410189 June 2038 use U-4024 11028100 April 2038 substance, product 10851091 July 2036 substance, product 9650393 July 2036 substance, product 11760753 July 2036 use U-4024 8343955 September 2030 use U-4024 8242104 September 2030 substance, product
Regulatory exclusivity Code Expires NCE October 2029
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.